FMX101
CU-10201-301
Phase 3 small_molecule completed
Quick answer
FMX101 for Acne Vulgaris is a Phase 3 program (small_molecule) at Cutia Therapeutics (Shanghai) Co., Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cutia Therapeutics (Shanghai) Co., Ltd
- Indication
- Acne Vulgaris
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed